Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity. CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24
治疗前血清 CEACAM1 处于规定范围内的患者在使用 CM24 治疗时表现出更高的总存活率 (OS) 和无进展存活率 (PFS)
Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer
用于患者选择的血清生物标志物的定义为开发癌症治疗方法提供了显著的优势
CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024
CEACAM1 抑制剂 CM24 目前正在 2 期随机胰腺癌研究中接受评估，主要结果预计将在 2024 年第四季度公布
REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity. CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).
以色列雷霍沃特，2024年11月4日（GLOBE NEWSWIRE）——开发克服肿瘤免疫逃避和耐药性的首创疗法的临床阶段公司紫色生物技术有限公司（“紫色生物技术” 或 “公司”）（纳斯达克/塔斯证券代码：PPBT）今天宣布，已将血清 CEACAM1 确定为另一种新的潜在血液生物标志物，可能有助于确定哪种转移性胰腺导管腺样体癌症（PDAC）患者最有可能从CM24的治疗中受益。CM24 是一种人源化单克隆抗体，可阻断 CEACAM1 结合，从而抑制其活性。CEACAM1 在某些肿瘤细胞、免疫细胞和中性粒细胞外陷阱 (NET) 上过度表达。
